BioVie reported the dosing for the first patient in its phase 2a clinical trial of BIV201 for the treatment of refractory ascites due to liver cirrhosis.

BioVie (OTCQB:BIVI) reported the dosing for the first patient in its phase 2a clinical trial of BIV201 for the treatment of refractory ascites due to liver cirrhosis.
As quoted in the press release:

The initial trial will evaluate a total of 6 patients at the McGuire Research Institute in Richmond, VA.
“We are excited to start this study and dose the first patient with our Orphan drug candidate BIV201 (continuous low-dose infusion terlipressin)” said Patrick Yeramian MD, Medical Director for BioVie. “There is a clear need for an effective drug therapy for patients with refractory ascites, as there are no FDA-approved drugs for this condition. These patients frequently develop life-threatening complications due to their disease and suffer from a poor quality of life. Our clinical objective is to improve their health status and reduce the need for hospitalizations.”

Click here to read the full press release.

Source: www.marketwired.com

ascites biv201 disease drug candidate drug therapy fda fda-approved first patient health liver Pharmaceutical Investing